TrialCard CEO Bouck Named to PharmaVOICE 100

Share Article

List honors individuals making innovative contributions to the life-sciences indistry

Mark Bouck, President and CEO of pharmaceutical services provider TrialCard, was named to the PharmaVoice 100 list this week. The list recognizes inspirational individuals for their positive contributions to the life-sciences industry. Nominees are selected based on substantive accounts describing how they have affected positive changes in their organizations and contributed to the betterment of the industry as a whole. Since assuming the helm of TrialCard in 2012, Bouck has guided the company’s transformation from a niche provider of co-pay savings programs to a full-service patient access (HUB) provider that delivers integrated solutions to help patients overcome barriers to therapy and achieve positive health outcomes.

“It is a tremendous honor to be named to the PharmaVOICE 100. The individuals who share this accolade represent some of the brightest minds in our industry, and I’m truly humbled to be considered in the same company with them,” said Bouck. Bouck was specifically highlighted by PharmaVOICE for the characteristics of Drive and Integrity, and he said those markers are key components of everything the company does. “This award is certainly reflective of our employees’ drive to make our vision of what a pharmaceutical services provider should be a reality,” he remarked. “In addition, the business of healthcare is ultimately a people business, so demonstrating the integrity to always do what is best for the patient is critically important to us.”

During Bouck’s tenure as TrialCard President and CEO the company has dramatically grown its HUB services division, which provides benefit investigation and prior authorization support, specialty pharmacy triage, nursing outreach and clinical support for patients, as well as analytic consulting services. The company has also grown its Virtual Engagement business line to provide tele-detail, tele-promotion, and patient lead generation campaigns in support of pharmaceutical manufacturers.

Awardees on the list will be honored at the annual PharmaVOICE 100 celebration, to be held on September 15, 2016 in New York City.

About TrialCard

TrialCard, Incorporated provides product access, medication adherence, and patient support services on behalf of pharmaceutical manufacturers. Founded in 2000, TrialCard has become the largest provider of patient access programs in the industry, processing over $1 billion in reimbursement benefits per year. TrialCard holds nine US patents related to the processing and marketing of patient access programs. The company is headquartered in Morrisville, North Carolina. For more information about TrialCard, please visit http://www.trialcard.com.

About PharmaVOICE

Published monthly, with the combined July/August PharmaVOICE 100 and November/December Year in Preview issues, PharmaVOICE is expressly written and designed to deliver the views, opinions, and insights of the executives who are shaping the direction of the dynamic and multifaceted life-sciences industry. PharmaVOICE reaches more than 41,000 BPA qualified subscribers and 100,000 users with its digital edition.

PharmaVOICE's unique horizontal editorial approach cuts across industry silos, providing a holistic overview of the life-sciences industry, addressing a range of topics from molecule through market. By engaging compelling personalities from diverse industry sectors, PharmaVOICE provides multiple perspectives on business challenges, trends, and topics. Editorial content sparks dialog, initiates debate, and opens the lines of communication to facilitate and improve business-to-business relationships. PharmaVOICE's multiple-perspective and in-depth original forums, feature articles, topics, and departments are audience-driven. PharmaVOICE provides executives with useful peer-to-peer insights on a broad range of business practices and topics to a wide range of life-science sectors. For more information visit http://www.pharmavoice.com.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Robert Hastings
Follow us on
Visit website